Axial skeletal malformations induced by acetazolamide in rabbits.
In order to evaluate the teratogenic potential of acetazolamide in rabbits, three groups of 18 artificially inseminated females were treated orally with 50, 100, or 150 mg/kg/day of acetazolamide on days 6-18 of gestation. These doses induced maternal acidosis and electrolyte changes, consistent with those reported in rats and considered to be a result of carbonic anhydrase inhibition, as well as reductions in maternal body weight gain. At cesarean sections, average fetal body weights in the acetazolamide groups were dose-dependently decreased compared with controls. There were no effects of acetazolamide on embryonic survival or external morphology of live fetuses. In the fetal skeletal examination, thoracic and lumbar vertebral malformations occurred in 0.7%, 3.9%, and 6.1% of fetuses in the 50, 100, and 150 mg/kg/day groups, respectively, compared with none in the control group. In addition, missing vertebra was seen in a small number of fetuses in the 100 and 150 mg/kg/day groups. These axial skeletal malformations were, in some cases, associated with costal malformations. These results indicate that acetazolamide at maternotoxic doses can produce axial skeletal malformations in the rabbit.
Nakatsuka
T
T
Development Research Laboratories, Banyu Pharmaceutical Co., Ltd., Saitama-ken, Japan.
Komatsu
T
T
Fujii
T
T
D000086:Acetazolamide / Q000633:toxicity*; D000818:Animals; D001842:Bone and Bones / Q000002:abnormalities* / Q000187:drug effects*; D005260:Female; D011247:Pregnancy; D011817:Rabbits / Q000196:embryology*; D013723:Teratogens / Q000633:toxicity*
D013723:Teratogens; D000086:Acetazolamide